

Riccardo Giampieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1122073/publications.pdf>

Version: 2024-02-01

57
papers

980
citations

471061

17
h-index

476904

29
g-index

59
all docs

59
docs citations

59
times ranked

2072
citing authors

#	ARTICLE	IF	CITATIONS
1	New Insights into Hormonal Therapies in Uterine Sarcomas. <i>Cancers</i> , 2022, 14, 921.	1.7	10
2	Influence of type 2 diabetes mellitus and concomitant anti-diabetic medications in patients with metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16301-e16301.	0.8	0
3	Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4153-4153.	0.8	0
4	Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO). <i>Supportive Care in Cancer</i> , 2021, 29, 851-858.	1.0	0
5	An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer. <i>Oncology Letters</i> , 2021, 21, 267.	0.8	1
6	Seroprevalence of SARS-CoV-2â€™Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1503.	1.0	12
7	Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 69.	1.3	16
8	BRCA mutations and gastrointestinal cancers: When to expect the unexpected?. <i>World Journal of Clinical Oncology</i> , 2021, 12, 565-580.	0.9	10
9	Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. <i>Current Oncology</i> , 2021, 28, 3525-3536.	0.9	2
10	Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab. <i>Frontiers in Oncology</i> , 2021, 11, 736104.	1.3	8
11	BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2021, 13, 5741-5751.	0.6	5
12	Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Related Hypokalaemia. <i>Oncology and Therapy</i> , 2020, 8, 161-169.	1.0	1
13	Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing. <i>Cancers</i> , 2020, 12, 2724.	1.7	5
14	<p>Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Optimal Management</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 663-672.	0.9	17
15	<p>Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9363-9374.	0.9	40
16	Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis. <i>Lung Cancer</i> , 2020, 146, 318-326.	0.9	9
17	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. <i>Targeted Oncology</i> , 2020, 15, 115-126.	1.7	15
18	Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102974.	2.0	17

#	ARTICLE	IF	CITATIONS
19	Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival. <i>Frontiers in Oncology</i> , 2019, 9, 874.	1.3	48
20	Clinical impact of different exosomesâ€™ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. <i>PLoS ONE</i> , 2019, 14, e0215990.	1.1	24
21	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 591-597.	0.5	6
22	BRAF-mutant colorectal cancer, a different breed evolving. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 499-512.	1.5	19
23	A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay. <i>Familial Cancer</i> , 2018, 17, 215-224.	0.9	1
24	Optimal management of resected gastric cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 1605-1618.	0.9	16
25	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: TheÂTOREADOR Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e601-e615.	1.0	18
26	Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 55.	0.5	9
27	Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. <i>Gastric Cancer</i> , 2017, 20, 156-163.	2.7	62
28	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 106-116.	2.0	33
29	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. <i>Scientific Reports</i> , 2017, 7, 45703.	1.6	22
30	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017, 20, 825-833.	2.7	32
31	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017, 13, 2265-2275.	1.1	10
32	Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. <i>BioMed Research International</i> , 2016, 2016, 1-7.	0.9	45
33	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2016, 6, 25195.	1.6	25
34	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 99-106.	2.0	11
35	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1Î±â€™Final results of the ALICE-2 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 280-280.	0.8	13
36	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiALdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15116-e15116.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. SpringerPlus, 2015, 4, 743.	1.2	10
38	Prognostic Value for Incidental Antihypertensive Therapy With β -Blockers in Metastatic Colorectal Cancer. Medicine (United States), 2015, 94, e719.	0.4	18
39	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget, 2015, 6, 35087-35094.	0.8	40
40	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. OncoTargets and Therapy, 2015, 8, 1149.	1.0	5
41	Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. Journal of Translational Medicine, 2015, 13, 140.	1.8	6
42	Maintenance therapy for metastatic colorectal cancer. Lancet Oncology, The, 2015, 16, 1281-1282.	5.1	2
43	Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?. Oncotarget, 2015, 6, 38737-38748.	0.8	25
44	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy.. Journal of Clinical Oncology, 2015, 33, e15126-e15126.	0.8	0
45	Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study. Anticancer Research, 2015, 35, 2391-9.	0.5	1
46	The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treatment Reviews, 2014, 40, 934-941.	3.4	16
47	The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. Molecules, 2014, 19, 6393-6406.	1.7	56
48	Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients. Current Drug Targets, 2014, 15, 1225-1230.	1.0	7
49	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics, 2013, 14, 1991-1998.	0.6	17
50	Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Critical Reviews in Oncology/Hematology, 2013, 88, 272-283.	2.0	27
51	Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach. PLoS ONE, 2013, 8, e78544.	1.1	14
52	Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients. PLoS ONE, 2013, 8, e72843.	1.1	36
53	Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients. PLoS ONE, 2012, 7, e38192.	1.1	15
54	Correlation of activated AKT and MAPK expression in liver metastases with clinical outcome in colorectal cancer patients receiving irinotecan/cetuximab treatment.. Journal of Clinical Oncology, 2012, 30, 449-449.	0.8	0

#	ARTICLE	IF	CITATIONS
55	The Role of HER β Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. <i>Oncologist</i> , 2011, 16, 53-60.	1.9	55
56	Insulin-like growth factor 1 expression correlates with clinical outcome in K β RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. <i>International Journal of Cancer</i> , 2010, 127, 1941-1947.	2.3	67
57	Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	1